Clinical profile of saruplase: mortality and safety.
The data from 6775 patients treated with saruplase were analysed to provide an overview of the clinical profile of this thrombolytic agent. Death and reinfarction rates were calculated to assess efficacy. Thirty-day mortality was 5.7% and the reinfarction rate was 5.3%. Total stroke rate was 1.3% (cerebral haemorrhage 0.6%), whereas severe bleeding was seen in 2.5% of patients. Finally, there was no conclusive evidence of allergic reactions following drug administration. As compared with other currently available thrombolytic agents, saruplase appears to be safe and effective.
Betriu
A
A
Institut de Malalties Cardiovasculars, Hospital Clinic, University of Barcelona, Spain.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002543:Cerebral Hemorrhage / Q000209:etiology* / Q000401:mortality; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012008:Recurrence; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D014568:Urokinase-Type Plasminogen Activator; C067551:saruplase